Pharmaceuticals
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
* GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). * Results on the primary endpoint showed that sugemalimab significantly improved objective res...
2022-06-04 08:02
8423
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innoven...
2022-06-02 20:08
4687
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022
SUZHOU, China, June 2, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that clinical data for...
2022-06-02 08:08
4032
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares
SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...
2022-06-02 08:00
7462
Cambrex Acquires Leading EU Stability Storage Company Q1 Scientific
EAST RUTHERFORD, NJ, June 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a leading pr...
2022-06-01 18:00
3533
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
* LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research * Safety profile is favourable and consistent with previous HMTM studies * TauRx will now pursue regulatory ...
2022-06-01 16:00
2679
AMGEN AND NSG BIOLABS ANNOUNCE GOLDEN TICKET TO BOOST SINGAPORE'S BIOTECH ECOSYSTEM
Amgen is the inaugural sponsor of the NSG Tomorrow Programme that aims to
support innovation among biotech startups inSoutheast Asia
SINGAPORE, June 1, 2022 /PRNewswire/ -- Amgen
2022-06-01 10:00
4478
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director
SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-06-01 08:00
4562
CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights
SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results a...
2022-06-01 00:35
7236
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...
2022-05-31 22:30
5437
Nalagenetics obtains CE Mark for its pharmacogenomics software, Nala Clinical Decision Support™ Module- PGx Core
SINGAPORE, May 31, 2022 /PRNewswire/ -- Nalagenetics has just completed CE-marking for one of the reporting modules of its Clinical Decision Support (CDS) software. The registration enables its software to be marketed in Europe and support further approval inSoutheast Asia, where it aims to gain...
2022-05-31 21:09
4058
Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai Announce Joint Center for Engineering and Precision Medicine
NEW YORK, May 31, 2022 /PRNewswire/ -- Rensselaer Polytechnic Institute and the Icahn School of Medicine atMount Sinai recently announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science ...
2022-05-31 21:00
4224
Medical training in Vietnam impressively attracts international students.
HO CHI MINH CITY, Vietnam, May 30, 2022 /PRNewswire/ -- In the last few days of May, many colleagues fromIndia, Honduras, Nigeria, etc., came to Vietnam to be admitted to the Medical Major of Hong BangInternational University (HIU). This is a significant milestone for the Vietnamese board of educ...
2022-05-30 20:08
4193
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
GAITHERSBURG, Md. and SUZHOU, China, May 30, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the launch of a Phase I clinical trial of the Company's si...
2022-05-30 16:40
3835
United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria
TAIPEI, May 30, 2022 /PRNewswire/ -- Taiwan-based United BioPharma (UBP) has
announced the approval of a Phase 2 clinical trial with novel anti-IgE
monoclonal antibody UB-221 by the Taiwan Food and Drug Administration (TFDA).
2022-05-30 10:59
2468
MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval, making it the first limus DEB to be available to US patients
GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR was also the first DEB (Drug Eluting Balloon) granted "breakthrough device de...
2022-05-30 08:00
3646
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN DIEGO and SUZHOU, Chi...
2022-05-27 09:30
6920
Menarini inaugurates new regional headquarters in Dubai, UAE
The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across theMiddle East and Africa (MEA) region with innovative products and breakthrough research DUBAI, UAE, May 26, 2022 /PRNewswire/ -- Menarini, the leading Italian pharmaceutical gro...
2022-05-26 23:16
4427
US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
Key Highlights: * US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company * Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of ne...
2022-05-26 20:44
3517
OLON ANNOUNCES THE CREATION OF A MAJOR CENTER OF RESEARCH AND DEVELOPMENT IN ITALY, THAT WILL GIVE RISE TO AN INNOVATIVE GLOBAL R&D MODEL
MILAN, May 26, 2022 /PRNewswire/ -- Olon, Leading API supplier, announces the creation of an R&D hub at its center inMilan, home to the Group's headquarters, paving the way for further major expansion and diversification of its expertise applied to the development of APIs for the CDMO and Generic...
2022-05-26 19:00
2607
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 263 media titles]
2026-10-06 11:40
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9864
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
9779
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
9007
